Literature DB >> 20951916

The safety of drugs used in acid-related disorders and functional gastrointestinal disorders.

Neehar Parikh1, Colin W Howden.   

Abstract

Medicines are frequently used in the management of acid-related disorders and functional gastrointestinal disorders. With the exception of complicated peptic ulcer disease, these disorders are not associated with appreciable mortality. Drug treatments have consequently been held to the highest standards of safety. Some medicines have been withdrawn or restricted based on assessments and perceptions of risk. However, the risk of serious toxicity is low for most of the agents discussed in this article. Assessments are made of the safety and adverse-event profiles of certain drug classes and, where appropriate, individual medicines. For conditions with a low risk of mortality or serious morbidity, clinicians need to balance the risks of potential adverse events with the anticipated benefits of a successful outcome of specific drug treatment.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20951916      PMCID: PMC3117659          DOI: 10.1016/j.gtc.2010.08.009

Source DB:  PubMed          Journal:  Gastroenterol Clin North Am        ISSN: 0889-8553            Impact factor:   3.806


  70 in total

1.  Editorial: just how "difficult" is it to withdraw PPI treatment?

Authors:  Colin W Howden; Peter J Kahrilas
Journal:  Am J Gastroenterol       Date:  2010-07       Impact factor: 10.864

2.  Dyspeptic symptom development after discontinuation of a proton pump inhibitor: a double-blind placebo-controlled trial.

Authors:  Anna Niklasson; Lina Lindström; Magnus Simrén; Greger Lindberg; Einar Björnsson
Journal:  Am J Gastroenterol       Date:  2010-03-23       Impact factor: 10.864

Review 3.  Systematic review: Proton pump inhibitor-associated acute interstitial nephritis.

Authors:  F Sierra; M Suarez; M Rey; M F Vela
Journal:  Aliment Pharmacol Ther       Date:  2007-08-15       Impact factor: 8.171

4.  Proton pump inhibitors in the management of GERD.

Authors:  Philip O Katz; Stacey Zavala
Journal:  J Gastrointest Surg       Date:  2009-09-23       Impact factor: 3.452

5.  Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss.

Authors:  Laura E Targownik; Lisa M Lix; Stella Leung; William D Leslie
Journal:  Gastroenterology       Date:  2009-11-18       Impact factor: 22.682

6.  Clinical trial: renzapride treatment of women with irritable bowel syndrome and constipation - a double-blind, randomized, placebo-controlled, study.

Authors:  A J Lembo; F Cremonini; N Meyers; R Hickling
Journal:  Aliment Pharmacol Ther       Date:  2010-02-16       Impact factor: 8.171

7.  Long-term tegaserod treatment for dysmotility-like functional dyspepsia: results of two identical 1-year cohort studies.

Authors:  William D Chey; Colin W Howden; Jan Tack; Gregory Ligozio; David L Earnest
Journal:  Dig Dis Sci       Date:  2009-12-03       Impact factor: 3.199

8.  Long-term gastroesophageal reflux disease therapy improves reflux symptoms in elderly patients: five-year prospective study in community medicine.

Authors:  Masaki Miyamoto; Ken Haruma; Masao Kuwabara; Makoto Nagano; Takeshi Okamoto; Mio Tanaka
Journal:  J Gastroenterol Hepatol       Date:  2007-05       Impact factor: 4.029

9.  A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS.

Authors:  Richard Krause; Vanessa Ameen; Susan H Gordon; Marquita West; Amy T Heath; Teresa Perschy; Eric G Carter
Journal:  Am J Gastroenterol       Date:  2007-05-17       Impact factor: 10.864

Review 10.  Clostridium difficile: changing epidemiology and new treatment options.

Authors:  Ed J Kuijper; Jaap T van Dissel; Mark H Wilcox
Journal:  Curr Opin Infect Dis       Date:  2007-08       Impact factor: 4.915

View more
  10 in total

1.  Paradoxically augmented anti-tumorigenic action of proton pump inhibitor and GastrininAPCMin/+ intestinal polyposis model.

Authors:  Young-Min Han; Ki Baik Hahm; Jong-Min Park; Sung Pyo Hong; Eun-Hee Kim
Journal:  Neoplasia       Date:  2014-01       Impact factor: 5.715

2.  The dose of omeprazole required to achieve adequate intraesophageal acid suppression in patients with gastroesophageal junction specialized intestinal metaplasia and Barrett's esophagus.

Authors:  Joshua T Watson; Fouad J Moawad; Ganesh R Veerappan; John T Bassett; Corinne L Maydonovitch; John D Horwhat; Roy K H Wong
Journal:  Dig Dis Sci       Date:  2013-07-04       Impact factor: 3.199

Review 3.  Proton pump inhibitors: impact on glucose metabolism.

Authors:  Diana Boj-Carceller
Journal:  Endocrine       Date:  2012-08-12       Impact factor: 3.633

4.  Symptom burden and consulting behavior in patients with overlapping functional disorders in the US population.

Authors:  Nimish Vakil; Margie Stelwagon; Elizabeth P Shea; Steve Miller
Journal:  United European Gastroenterol J       Date:  2015-08-06       Impact factor: 4.623

5.  Potassium-Competitive Acid Blockers (P-CABs): Are They Finally Ready for Prime Time in Acid-Related Disease?

Authors:  Richard H Hunt; Carmelo Scarpignato
Journal:  Clin Transl Gastroenterol       Date:  2015-10-29       Impact factor: 4.488

Review 6.  A Review of the Novel Application and Potential Adverse Effects of Proton Pump Inhibitors.

Authors:  Li-Yuan Yu; Lu-Ning Sun; Xue-Hui Zhang; Yue-Qi Li; Lei Yu; Zi-Qing-Yun Yuan; Ling Meng; Hong-Wen Zhang; Yong-Qing Wang
Journal:  Adv Ther       Date:  2017-04-20       Impact factor: 3.845

7.  Supplement With Calcium or Alendronate Suppresses Osteopenia Due to Long Term Rabeprazole Treatment in Female Mice: Influence on Bone TRAP and Osteopontin Levels.

Authors:  Aly A M Shaalan; Mohamed El-Sherbiny; Taghrid B El-Abaseri; Mohamed Z Shoaeir; Tarek M Abdel-Aziz; Magda I Mohamed; Sawsan A Zaitone; Hala M F Mohammad
Journal:  Front Pharmacol       Date:  2020-05-13       Impact factor: 5.810

8.  Therapeutic efficacy of proton transport inhibitors alone or in combination with cisplatin in triple negative and hormone sensitive breast cancer models.

Authors:  Enrica Balza; Sebastiano Carlone; Sonia Carta; Patrizia Piccioli; Vanessa Cossu; Cecilia Marini; Gianmario Sambuceti; Anna Rubartelli; Patrizia Castellani
Journal:  Cancer Med       Date:  2021-11-18       Impact factor: 4.452

9.  A Rare Case of Pseudomembranous Colitis Presenting with Pleural Effusion and Ascites with Literature Review.

Authors:  Hossain Salehi; Amir Mohammad Salehi
Journal:  Case Rep Gastrointest Med       Date:  2021-12-31

10.  Proton pump inhibitors protect mice from acute systemic inflammation and induce long-term cross-tolerance.

Authors:  E Balza; P Piccioli; S Carta; R Lavieri; M Gattorno; C Semino; P Castellani; A Rubartelli
Journal:  Cell Death Dis       Date:  2016-07-21       Impact factor: 8.469

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.